Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 714-723, December 2009

High-grade glioma mouse models and their applicability for preclinical testing

  • Nienke A. de Vries

      Affiliations

    • Department of Clinical Chemistry, The Netherlands Cancer Institute (Antoni van Leeuwenhoek Hospital), Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • Tel.: +31 20 512 1828.
  • ,
  • Jos H. Beijnen

      Affiliations

    • Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital), Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    • Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands
    • Tel.: +31 20 512 4342.
  • ,
  • Olaf van Tellingen

      Affiliations

    • Department of Clinical Chemistry, The Netherlands Cancer Institute (Antoni van Leeuwenhoek Hospital), Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 20 512 2792; fax: +31 20 512 2799.

Received 9 June 2009; received in revised form 15 August 2009; accepted 24 August 2009. published online 22 September 2009.

Summary 

High-grade gliomas (WHO grade III anaplastic astrocytoma and grade IV glioblastoma multiforme) are the most common primary tumors in the central nervous system in adults. Unfortunately, despite great efforts in finding better therapies, high-grade glioma remains among the most devastating and deadliest of all human cancers. During recent years, genetic and molecular alterations that underlie this disease have been identified and advanced our basic knowledge about gliomagenesis. Moreover, understanding the molecular biology has also led to the development of genetically engineered mouse models that resemble many of the features of human gliomas. Ideally, such “patient-like” models should be instrumental for preclinical testing of novel therapeutics, but thus far they have not yet been widely implemented for this purpose. This review will discuss the advantages and shortcomings of the established high-grade glioma mouse models with emphasis on their potential applicability for preclinical testing of novel drugs and treatment regimens.

Keywords: Glioma, Mouse models, Genetic engineering, Intervention studies, Non-invasive imaging

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0305-7372(09)00124-8

doi:10.1016/j.ctrv.2009.08.011

Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 714-723, December 2009